Literature DB >> 10551848

Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites.

M Asahi1, Y Kimura, K Kurzydlowski, M Tada, D H MacLennan.   

Abstract

In an earlier study (Kimura, Y., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1997) J. Biol. Chem. 272, 15061-15064), mutation of amino acids on one face of the phospholamban (PLN) transmembrane helix led to loss of PLN inhibition of sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA) molecules. This helical face was proposed to form a site of PLN interaction with a transmembrane helix in SERCA molecules. To determine whether predicted transmembrane helices M4, M5, M6, or M8 in SERCA1a interact with PLN, SERCA1a mutants were co-expressed with wild-type PLN and effects on Ca(2+) dependence of Ca(2+) transport were measured. Wild-type inhibitory interactions shifted apparent Ca(2+) affinity of SERCA1a by an average of -0.34 pCa units, but four of the seven mutations in M4 led to a more inhibitory shift in apparent Ca(2+) affinity, averaging -0.53 pCa units. Seven mutations in M5 led to an average shift of -0.32 pCa units and seven mutations in M8 led to an average shift of -0.30 pCa units. Among 11 mutations in M6, 1, Q791A, increased the inhibitory shift (-0.59 pCa units) and 5, V795A (-0.11), L802A (-0.07), L802V (-0.04), T805A (-0.11), and F809A (-0.12), reduced the inhibitory shift, consistent with the view that Val(795), Leu(802), Thr(805), and Phe(809), located on one face of a predicted M6 helix, form a site in SERCA1a for interaction with PLN. Those mutations in M4, M6, or M8 of SERCA1a that enhanced PLN inhibitory function did not enhance PLN physical association with SERCA1a, but mutants V795A and L802A in M6, which decreased PLN inhibitory function, decreased physical association, as measured by co-immunoprecipitation. In related studies, those PLN mutants that gained inhibitory function also increased levels of co-immunoprecipitation of wild-type SERCA1a and those that lost inhibitory function also reduced association, correlating functional interaction sites with physical interaction sites. Thus, both functional and physical data confirm that PLN interacts with M6 SERCA1a.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551848     DOI: 10.1074/jbc.274.46.32855

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Phospholamban domain IB forms an interaction site with the loop between transmembrane helices M6 and M7 of sarco(endo)plasmic reticulum Ca2+ ATPases.

Authors:  M Asahi; N M Green; K Kurzydlowski; M Tada; D H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

2.  Locating phospholamban in co-crystals with Ca(2+)-ATPase by cryoelectron microscopy.

Authors:  H S Young; L R Jones; D L Stokes
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

Review 3.  Structural similarities of Na,K-ATPase and SERCA, the Ca(2+)-ATPase of the sarcoplasmic reticulum.

Authors:  K J Sweadner; C Donnet
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 4.  What the structure of a calcium pump tells us about its mechanism.

Authors:  A G Lee; J M East
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

5.  Direct activation of gastric H,K-ATPase by N-terminal protein kinase C phosphorylation. Comparison of the acute regulation mechanisms of H,K-ATPase and Na,K-ATPase.

Authors:  Flemming Cornelius; Yasser A Mahmmoud
Journal:  Biophys J       Date:  2003-03       Impact factor: 4.033

6.  Cardiac-specific overexpression of sarcolipin inhibits sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA2a) activity and impairs cardiac function in mice.

Authors:  Michio Asahi; Kinya Otsu; Hiroyuki Nakayama; Shungo Hikoso; Toshihiro Takeda; Anthony O Gramolini; Maria G Trivieri; Gavin Y Oudit; Takashi Morita; Yoichiro Kusakari; Shuta Hirano; Kenichi Hongo; Shinichi Hirotani; Osamu Yamaguchi; Alan Peterson; Peter H Backx; Satoshi Kurihara; Masatsugu Hori; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-16       Impact factor: 11.205

7.  The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum.

Authors:  Brandy L Akin; Thomas D Hurley; Zhenhui Chen; Larry R Jones
Journal:  J Biol Chem       Date:  2013-08-31       Impact factor: 5.157

8.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Authors:  Kobra Haghighi; Fotis Kolokathis; Anthony O Gramolini; Jason R Waggoner; Luke Pater; Roy A Lynch; Guo-Chang Fan; Dimitris Tsiapras; Rohan R Parekh; Gerald W Dorn; David H MacLennan; Dimitrios Th Kremastinos; Evangelia G Kranias
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

9.  Structural constraints on the transmembrane and juxtamembrane regions of the phospholamban pentamer in membrane bilayers: Gln29 and Leu52.

Authors:  Wei Liu; Jeffrey Z Fei; Toru Kawakami; Steven O Smith
Journal:  Biochim Biophys Acta       Date:  2007-10-22

10.  The sarcolipin-bound calcium pump stabilizes calcium sites exposed to the cytoplasm.

Authors:  Anne-Marie L Winther; Maike Bublitz; Jesper L Karlsen; Jesper V Møller; John B Hansen; Poul Nissen; Morten J Buch-Pedersen
Journal:  Nature       Date:  2013-03-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.